Shopping Cart 0
Cart Subtotal
USD 0

Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Astellas Pharma Inc (4503)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company's product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc Key Recent Developments

Oct 23,2018 Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App

Oct 16,2018 Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

Oct 09,2018 Astellas details progress and commitment to patients and the community in the company's americas 2017 corporate social responsibility report card

Oct 09,2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Astellas Pharma Inc-Key Facts 6

Astellas Pharma Inc-Key Employees 7

Astellas Pharma Inc-Key Employee Biographies 11

Astellas Pharma Inc-Major Products and Services 12

Astellas Pharma Inc-History 15

Astellas Pharma Inc-Company Statement 27

Astellas Pharma Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Joint Venture 33

Section 2-Company Analysis 35

Company Overview 35

Astellas Pharma Inc-Business Description 36

Product Category: Betanis/Myrbetriq/BETMIGA 36

Performance 36

Product Category: Other 37

Performance 37

Product Category: Prograf 37

Performance 37

Product Category: Vesicare 37

Performance 37

Product Category: XTANDI 37

Performance 37

Geographical Segment: Americas 37

Performance 37

Geographical Segment: Asia and Oceania 37

Performance 37

Geographical Segment: EMEA 37

Performance 37

Geographical Segment: Japan 38

Performance 38

R&D Overview 38

Astellas Pharma Inc-Corporate Strategy 39

Astellas Pharma Inc-SWOT Analysis 40

SWOT Analysis-Overview 40

Astellas Pharma Inc-Strengths 40

Astellas Pharma Inc-Weaknesses 41

Astellas Pharma Inc-Opportunities 42

Astellas Pharma Inc-Threats 43

Astellas Pharma Inc-Key Competitors 44

Section 3-Company Financial Ratios 45

Financial Ratios-Capital Market Ratios 45

Financial Ratios-Annual Ratios 46

Performance Chart 49

Financial Performance 49

Financial Ratios-Interim Ratios 50

Financial Ratios-Ratio Charts 51

Section 4-Company's Lifesciences Financial Deals and Alliances 52

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Astellas Pharma Inc, Recent Deals Summary 54

Section 5-Company's Recent Developments 55

Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 55

Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 56

Oct 16, 2018: Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day 57

Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company's americas 2017 corporate social responsibility report card 60

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 61

Oct 05, 2018: Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program 62

Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 66

Aug 14, 2018: Astellas Pharma acquires Quethera for USD 108.5m 67

Jun 08, 2018: Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas 68

May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 69

Section 6-Appendix 70

Methodology 70

Ratio Definitions 70

About GlobalData 74

Contact Us 74

Disclaimer 74


List Of Figure

List of Figures

Astellas Pharma Inc, Performance Chart (2014-2018) 49

Astellas Pharma Inc, Ratio Charts 51

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53


List Of Table

List of Tables

Astellas Pharma Inc, Key Facts 6

Astellas Pharma Inc, Key Employees 7

Astellas Pharma Inc, Key Employees (cont..) 10

Astellas Pharma Inc, Key Employee Biographies 11

Astellas Pharma Inc, Major Products and Services 12

Astellas Pharma Inc, History 15

Astellas Pharma Inc, Other Locations 28

Astellas Pharma Inc, Subsidiaries 28

Astellas Pharma Inc, Joint Venture 33

Astellas Pharma Inc, Key Competitors 44

Astellas Pharma Inc, Ratios based on current share price 45

Astellas Pharma Inc, Annual Ratios 46

Astellas Pharma Inc, Annual Ratios (Cont...1) 47

Astellas Pharma Inc, Annual Ratios (Cont...2) 48

Astellas Pharma Inc, Interim Ratios 50

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Astellas Pharma Inc, Recent Deals Summary 54

Currency Codes 70

Capital Market Ratios 70

Equity Ratios 71

Profitability Ratios 71

Cost Ratios 72

Liquidity Ratios 72

Leverage Ratios 73

Efficiency Ratios 73

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Astellas Pharma Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Takeda Pharmaceutical Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Eisai Co Ltd

Daiichi Sankyo Co Ltd